Literature DB >> 12089673

Conjugate vaccines against group B Streptococcus types IV and VII.

Lawrence C Paoletti1, Dennis L Kasper.   

Abstract

Although rarely encountered, group B Streptococcus (GBS) types IV and VII have been isolated from infants and adults with invasive disease. This study was designed to determine the immunogenicity and efficacy in animals of conjugate vaccines prepared with GBS types IV and VII capsular polysaccharide (CPS). Despite the striking similarities in structure of these 2 carbohydrate antigens, high-titer rabbit antiserum to each conjugate vaccine was serotype specific. Active vaccination of female mice with the conjugate vaccines induced type-specific IgG and resulted in survival of >90% of newborn pups challenged with viable GBS of homologous serotype. If needed, types IV and VII CPS conjugate vaccines of the design described can be added to the formulation of a multivalent GBS vaccine.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12089673     DOI: 10.1086/341073

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  11 in total

1.  Characterization of a novel leucine-rich repeat protein antigen from group B streptococci that elicits protective immunity.

Authors:  Ravin Seepersaud; Sean B Hanniffy; Peter Mayne; Phil Sizer; Richard Le Page; Jerry M Wells
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

Review 2.  Recent advances in understanding the molecular basis of group B Streptococcus virulence.

Authors:  Heather C Maisey; Kelly S Doran; Victor Nizet
Journal:  Expert Rev Mol Med       Date:  2008-09-22       Impact factor: 5.600

3.  Transmission probabilities and durations of immunity for three pathogenic group B Streptococcus serotypes.

Authors:  Bethany Percha; M E J Newman; Betsy Foxman
Journal:  Infect Genet Evol       Date:  2011-05-14       Impact factor: 3.342

4.  Phenotypic and genotypic characterization of group B streptococcal isolates in southern Brazil.

Authors:  Jussara K Palmeiro; Libera M Dalla-Costa; Sérgio E L Fracalanzza; Ana C N Botelho; Keite da Silva Nogueira; Mara C Scheffer; Rosângela S L de Almeida Torres; Newton Sérgio de Carvalho; Laura Lúcia Cogo; Humberto M F Madeira
Journal:  J Clin Microbiol       Date:  2010-09-29       Impact factor: 5.948

Review 5.  Group B Streptococcus: global incidence and vaccine development.

Authors:  Atul Kumar Johri; Lawrence C Paoletti; Philippe Glaser; Meenakshi Dua; Puja Kumari Sharma; Guido Grandi; Rino Rappuoli
Journal:  Nat Rev Microbiol       Date:  2006-11-06       Impact factor: 60.633

Review 6.  Group B Streptococcus vaccine: state of the art.

Authors:  Annalisa Nuccitelli; C Daniela Rinaudo; Domenico Maione
Journal:  Ther Adv Vaccines       Date:  2015-05

7.  TLR4-dependent adjuvant activity of Neisseria meningitidis lipid A.

Authors:  Susu Zughaier; Liana Steeghs; Peter van der Ley; David S Stephens
Journal:  Vaccine       Date:  2007-04-02       Impact factor: 3.641

8.  Protection against Streptococcus suis Serotype 2 Infection Using a Capsular Polysaccharide Glycoconjugate Vaccine.

Authors:  Guillaume Goyette-Desjardins; Cynthia Calzas; Tze Chieh Shiao; Axel Neubauer; Jennifer Kempker; René Roy; Marcelo Gottschalk; Mariela Segura
Journal:  Infect Immun       Date:  2016-06-23       Impact factor: 3.441

Review 9.  Understanding the regulation of Group B Streptococcal virulence factors.

Authors:  Lakshmi Rajagopal
Journal:  Future Microbiol       Date:  2009-03       Impact factor: 3.165

10.  Progress toward a group B streptococcal vaccine.

Authors:  Joon Young Song; Jae Hyang Lim; Sangyong Lim; Zhi Yong; Ho Seong Seo
Journal:  Hum Vaccin Immunother       Date:  2018-07-16       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.